In the aggressive subtype of triple-negative breast cancer, RAGE serves as a cell plasticity driver.

Published Date: 09 Aug 2023

Josep Villanueva, an Investigator at the Vall d'Hebron Institute of Oncology (VHIO), is the lead author of a study that was published online ahead of print in the journal Oncogene. The study demonstrates that the receptor for advanced glycation end-product (RAGE) is involved in cancer development.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot